A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Latest Information Update: 03 Feb 2023
At a glance
- Drugs Pembrolizumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 03 Jan 2023 Status changed from recruiting to discontinued due to lack of accrual.
- 29 Aug 2022 Planned End Date changed from 10 Aug 2022 to 10 Aug 2023.
- 29 Aug 2022 Planned primary completion date changed from 10 Aug 2022 to 10 Aug 2023.